Company news
Travere Therapeutics, Inc. (NASDAQ:TVTX) news
Travere Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment…
Press releases & updates
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
October 2, 2026
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
October 1, 2026
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
September 23, 2026
Travere Therapeutics Announces Planned Chief Executive Officer Transition
September 21, 2026
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Travere Therapeutics Reports Second Quarter 2026 Financial Results
August 4, 2026
Travere Therapeutics to Report Second Quarter 2026 Financial Results
July 28, 2026
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
June 16, 2026
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
June 3, 2026
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
June 2, 2026
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
May 27, 2026
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 6, 2026
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 5, 2026
Travere Therapeutics Reports First Quarter 2026 Financial Results
May 3, 2026
Travere Therapeutics to Report First Quarter 2026 Financial Results
April 27, 2026
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
April 14, 2026
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
April 12, 2026
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
February 19, 2026
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
February 4, 2026
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
January 13, 2026
Travere Therapeutics Provides Corporate Update and 2026 Outlook
January 11, 2026
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
November 5, 2025
Travere Therapeutics to Participate at Upcoming Investor Conferences
November 3, 2025
Travere Therapeutics Reports Third Quarter 2025 Financial Results
October 29, 2025
Travere Therapeutics to Report Third Quarter 2025 Financial Results
October 22, 2025
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
October 16, 2025
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
September 25, 2025
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
September 9, 2025
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
September 2, 2025
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
August 26, 2025
Travere Therapeutics Reports Second Quarter 2025 Financial Results
August 6, 2025
Travere Therapeutics to Report Second Quarter 2025 Financial Results
July 29, 2025
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
June 10, 2025
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
June 9, 2025
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
June 2, 2025
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
May 22, 2025
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
May 14, 2025
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
May 13, 2025
Travere Therapeutics Reports First Quarter 2025 Financial Results
April 30, 2025
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
April 28, 2025
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
April 28, 2025
Travere Therapeutics to Report First Quarter 2025 Financial Results
April 23, 2025
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
March 30, 2025
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
March 16, 2025
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 19, 2025
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 12, 2025
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
February 10, 2025
Travere Therapeutics Provides Corporate Update and 2025 Outlook
January 12, 2025